PDA

View Full Version : Myelodysplatic syndromes


  1. CuraGen and TopoTarget Announce Initiation of NCI-sponsored Phase II Clinical Trial o
  2. Role for proteomics in identifying hematologic malignancies
  3. Pharmion Announces FDA Acceptance of IND for Oral Azacitidine
  4. Myelodysplastic Syndromes
  5. Myelodysplastic Syndrome Basics I
  6. Risk Based Management
  7. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid
  8. Exjade
  9. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence
  10. Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
  11. Pancytopenia MDS may reflect stromal changes and longer time to engraftment post tran
  12. MDS FISH Testing
  13. Epigenetics and MDS
  14. Intravenous iron improves treatment response in cancer-related anemia
  15. Data show Vidaza benefits patients with MDS
  16. 59-Year-Old Man with MDS
  17. Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implicat
  18. Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study
  19. Improved Diagnosis Of Myelodysplastic Syndromes Following Genetic Mutation Discovery
  20. PARP Inhibitors for Myelodysplatic Syndromes
  21. Update on Developments in the Diagnosis and Prognostic Evaluation Patients With MDS
  22. Blood Tests for Myelodysplastic Syndromes
  23. Treatment of MDS is Changing
  24. Targeting errant immune system enzyme kills myelodysplastic cells